Vyome Holdings Reports 45% Revenue Growth but Increased Net Loss Following Merger

Vyome Holdings, Inc., formerly known as ReShape Lifesciences, Inc., reported significant financial developments in its latest 10-Q filing for the nine months ending September 30, 2025. The company generated revenue of $283,163, marking an increase of 45% from $195,516 in the same period last year. However, the company also reported a net loss of $9,198,033, a substantial rise from the $1,140,904 loss recorded in the previous year. This increase in losses is attributed to heightened operational expenses, particularly a notable $7.7 million in transactional and financial advisory fees related to the recent merger with Vyome Therapeutics, which was completed on August 15, 2025.

The merger has led to significant organizational changes, including a new management team and a shift in focus towards advancing the development of immuno-inflammatory assets. The company’s total assets surged to $7.05 million as of September 30, 2025, compared to $1.38 million at the end of 2024, primarily due to the merger and subsequent capital raises. The company’s cash and cash equivalents increased dramatically to $5.7 million from just $101,904 at the end of the previous fiscal year, reflecting successful financing activities, including a private placement that raised approximately $5.7 million.

Operationally, Vyome has shifted its focus to its biotechnology segment, which includes the development of several product candidates, such as VT-1953, a topical gel for treating malignant fungating wounds. The company is planning discussions with the FDA regarding pivotal trial protocols in early 2026. The company also reported a decrease in research and development expenses to $210,006 from $217,864, as resources were concentrated on the merger process. The company’s general and administrative expenses rose significantly to $1.37 million, driven by increased legal and professional fees associated with the merger.

In terms of market presence, Vyome has established a licensing agreement with Sun Pharma for the commercialization of its Luliconazole topical cream in India, which has begun generating revenue. The company’s strategic focus on the U.S.-India innovation corridor aims to leverage its position in the biotechnology sector. The company anticipates that its existing cash reserves, along with proceeds from recent financing activities, will support its operations for at least the next 15 months, although it acknowledges the need for additional funding to continue its growth trajectory and complete clinical trials.

Looking ahead, Vyome Holdings is positioned to navigate the complexities of the biotechnology landscape while managing its operational costs and pursuing strategic partnerships. The company remains committed to advancing its product candidates through clinical development, although it recognizes the inherent risks and uncertainties associated with drug development and regulatory approvals.